3D Global Biotech Inc Ordinary Shares 6808
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 90.26
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
3D Global Biotech Inc is engaged in developing reconstruction of human tissues and organs and manufactures customized and personalized high-level medical devices.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 28
Comparables
Valuation
|
Metric
|
6808
|
6183
|
1786
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 23.35 | 46.19 |
Price/Book Value | 6.41 | 4.29 | 4.56 |
Price/Sales | 90.26 | 4.87 | 11.34 |
Price/Cash Flow | — | 18.09 | 32.99 |
Price/Earnings
6808
6183
1786
Financial Strength
|
Metric
|
6808
|
6183
|
1786
|
|---|---|---|---|
Quick Ratio | 8.89 | 2.40 | 6.21 |
Current Ratio | 9.15 | 2.47 | 6.92 |
Interest Coverage | −370.74 | 694.46 | 24.73 |
Quick Ratio
6808
6183
1786
Profitability
|
Metric
|
6808
|
6183
|
1786
|
|---|---|---|---|
Return on Assets (Normalized) | −17.27% | 13.71% | 8.16% |
Return on Equity (Normalized) | −18.83% | 19.04% | 11.20% |
Return on Invested Capital (Normalized) | −18.34% | 18.14% | 8.75% |
Return on Assets
6808
6183
1786
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Rbbjpkgjk | Zrwm | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Hvhrndwf | Vqwlfd | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Hqbsltq | Mwqbynq | $99.5 Bil | |
MRNA
| Moderna Inc | Ytnwrjm | Hpvzs | $38.8 Bil | |
ARGX
| argenx SE ADR | Zxyndjrg | Fdbmd | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Nmxylkld | Xtp | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Vszvhkgj | Xmjgn | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Pttdxrbk | Hrggrqc | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Scycpfhl | Gnwdt | $12.5 Bil | |
INCY
| Incyte Corp | Txlzmbf | Xhwmwh | $11.6 Bil |